For citations:
Kolomeytseva A.А., Kopachevskaia S.V., Orel N.F., Gorbunova V.A., Eskina T.Y., Fedyanin M.Y., Manzyuk L.V., Snegovoy A.V., Scriabina L.S., Mukhametshina G.Z., Odintsova A.S., Trusilova E.V., Mukhametgaleeva F.H., Sehina O.V., Vakhabova Y.V., Dobrova N.V., Chtrnoglazova E.V. THE COMPARISON OF THE THERAPEUTIC EQUIVALENCE OF OXALIPLATINRONC® (BRANCH “NAUKOPROFI” OF N.N. BLOKHIN RCRC) AND ELOXATIN® (AVENTIS PHARMA LTD, GREAT BRITAIN) IN MFOLFOX6 COMBINATION AS A FIRST LINE OF CHEMOTHERAPY IN PATIENTS WITH METASTATIC COLORECTAL CANCER. Malignant tumours. 2016;(4):58-67. (In Russ.) https://doi.org/10.18027/2224-5057-2016-4-58-67
Email this article 